To compare profiles of subjects with and without cervical dystonia (CD)-associated pain, to evaluate the contribution of pain and the motor component of CD on quality of life, and to compare the initial botulinum toxin treatment paradigm between pain groups, baseline data were used from the CD Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE), a multicenter, prospective, observational registry designed to capture real-world practices and outcomes for onabotulinumtoxinA CD treatment. Subjects were divided into no/mild pain [Pain Numeric Rating Scale (PNRS) score 0–3] and moderate/severe pain groups (PNRS score 4–10). Descriptive and differential statistics were utilized to compare groups. 1,037 subjects completed the first treatment session, reported baseline botulinum toxin status, and completed baseline PNRS. Those with no/mild pain were significantly older at baseline. Those subjects with moderate/severe pain had higher Toronto Western Spasmodic Torticollis Rating Scale Severity (17.7 ± 5.1 vs. 16.2 ± 5.6, p < 0.0001) and Disability (12.7 ± 6.1 vs. 7.5 ± 5.6, p < 0.0001). CD subjects with moderate/severe pain received a higher mean dose (177.3 ± 82.9 vs. 158.0 ± 67.1 U, p = 0.0001) of onabotulinumtoxinA and were injected in more muscles (4.1 ± 1.4 vs. 3.7 ± 1.2, p < 0.0001) at initial treatment. CD PROBE clearly demonstrates the frequency of pain in CD and substantiates its importance when determining an optimal treatment paradigm. Future analyses of CD PROBE will further our understanding of the treatment patterns and outcomes related to onabotulinumtoxinA therapy for this disabling condition.
To evaluate the efficacy, tolerability, and neutralizing antibodies in the treatment of cervical dystonia with onabotulinumtoxinA (BOTOX). Subjects received onabotulinumtoxinA (containing original bulk toxin) treatment in a 10-week open-label period (period 1). Eligible subjects who completed this period were randomized to onabotulinumtoxinA or placebo in a 10-week double-blind period (period 2). The primary outcome measures were the Cervical Dystonia Severity Scale and the physician Global Assessment Scale at week 6 in period 2. Serum samples for immunogenicity tests were taken at baseline and study exit. The potential impact of preexisting neutralizing antibodies (nAbs) was examined across subgroups for period 1 and by analysis of covariance for period 2. Of 214 subjects enrolled in period 1, 170 enrolled in period 2 and received placebo (n = 82) or onabotulinumtoxinA (n = 88). In period 1, subjects with preexisting nAbs responded similarly to those without preexisting nAbs. In period 2, onabotulinumtoxinA produced significantly greater improvements than placebo on the Cervical Dystonia Severity Scale (-1.81 vs -0.31 points; P = 0.012) and physician Global Assessment Scale (61.7% vs. 41.6% improved; P = 0.022) at the primary time point week 6, using baseline severity and neutralizing antibody (nAb) status at study entry as covariates. Two subjects seroconverted from nAb negative at baseline to nAb positive at study exit but remained responsive to onabotulinumtoxinA during both the open and blinded treatment periods. Rhinitis and treatment-related dysphagia were reported significantly more frequently with onabotulinumtoxinA than placebo. OnabotulinumtoxinA was well tolerated and more effective than placebo for the treatment of cervical dystonia. Subject nAb status at baseline was not a clear predictor of response to onabotulinumtoxinA.
Objective To evaluate whether the progression of individual motor features was influenced by early deep brain stimulation (DBS), a post hoc analysis of Unified Parkinson9s Disease Rating Scale–III (UPDRS-III) score (after a 7-day washout) was conducted from the 2-year DBS in early Parkinson disease (PD) pilot trial dataset. Methods The prospective pilot trial enrolled patients with PD aged 50–75 years, treated with PD medications for 6 months–4 years, and no history of dyskinesia or other motor fluctuations, who were randomized to receive optimal drug therapy (ODT) or DBS plus ODT (DBS + ODT). At baseline and 6, 12, 18, and 24 months, all patients stopped all PD therapy for 1 week (medication and stimulation, if applicable). UPDRS-III “off” item scores were compared between the ODT and DBS + ODT groups (n = 28); items with significant between-group differences were analyzed further. Results UPDRS-III “off” rest tremor score change from baseline to 24 months was worse in patients receiving ODT vs DBS + ODT (p = 0.002). Rest tremor slopes from baseline to 24 months favored DBS + ODT both “off” and “on” therapy (p < 0.001, p = 0.003, respectively). More ODT patients developed new rest tremor in previously unaffected limbs than those receiving DBS + ODT (p = 0.001). Conclusions These results suggest the possibility that DBS in early PD may slow rest tremor progression. Future investigation in a larger cohort is needed, and these findings will be tested in the Food and Drug Administration–approved, phase III, pivotal, multicenter clinical trial evaluating DBS in early PD. Classification of evidence This study provides Class II evidence that for patients with early PD, DBS may slow the progression of rest tremor.
Tremor is one of the most visible features of Parkinson's disease (PD), and the majority of PD patients experience tremor during the course of the disease. However, the distress caused by this cardinal motor feature for patients early in the course of their PD is commonly underappreciated. People living with early stage PD often experience intense embarrassment and difficulties due to their tremor that limit social interactions, and tremor frequently interferes with the ability to perform activities of daily living and simple tasks at home and work. Although tremor is primarily managed with medications, both tremor response and satisfaction with medical therapy are highly variable. This review offers an overview of reports of the patient experience of tremor in early stage PD and current management options for this cardinal motor feature.